natgillin/translations-raw huggingface dataset:
A nucleic acid according to claim 7, or a pharmaceutically acceptable salt thereof, for use as a medicament. 
Nukleinska kiselina prema zahtjevu 7, ili njena farmaceutski prihvatljiva sol, naznačena time da se upotrebljava kao lijek.
Process for recovery of sulphuric acid from a mixture comprising sulphuric acid and organic matter, comprising the step of contacting said mixture with an anion selective membrane, thus producing a sulphuric acid rich filtrate stream and a stream depleted in sulphuric acid, wherein said mixture originates from a contacting step wherein biomass is contacted with a fresh stream of sulphuric acid, and wherein said fresh stream of sulphuric acid is at least partly obtained from the filtrate that is obtained by said step of contacting said mixture with said anion selective membrane, and wherein said fresh stream of sulphuric acid further contains sulphuric acid that is obtained by burning H2S, which H2S is preferably obtained from a sulphate reduction step that is applied to a stream that is obtained from said stream depleted in sulphuric acid. 
Postupak za oporavljanje sumporne kiseline iz mješavine koja sadrži sumpornu kiselinu i organske tvari, naznačen time, da sadrži fazu spajanja spomenute mješavine s anionski selektivnom membranom, te time proizvodnju toka bogatog filtrata sumporne kiseline i ispražnjenje tijeka u sumpornoj kiselini, pri čemu spomenuta mješavina potiče iz faze spajanja gdje je biomasa u doticaju sa svježim tokom sumporne kiseline, i pri čemu je spomenuti svježi tok sumporne kiseline barem djelomično dobiven iz filtrata koji je dobiven u spomenutoj fazi spajanja spomenute mješavine sa spomenutom anionski selektivnom membranom, te pri čemu spomenuti svježi tok sumporne kiseline nadalje sadrži sumpornu kiselinu koja je dobivena izgaranjem H2S, a taj H2S je dobiven najbolje iz faze redukcije sulfata, koja se primjenjuje na tok koji je dobiven iz spomenutog ispražnjenja toka u sumpornoj kiselini.
Process according to claim 1, wherein said membrane is in a configuration of (parallel) flat plates, or as tubes, capillaries, spiral wound tubes, in which one fluid passes on the lumen side and the other passes on the outside. 
Postupak prema zahtjevu 1, naznačen time, da je spomenuta membrana konstruirana kao paralelno postavljene ravne ploče, ili kao cijevi, kapilarne cijevi, spiralno usječene cijevi, u kojima prolazi jedna tekućina na lumenoj strani, a druga prolazi s vanjske strane lumena.
Process according to any of the previous claims, wherein the transport of sulphuric acid across said membrane is effected by passing a receiving liquid on the filtrate side of the membrane, which receiving liquid is preferably water. 
Postupak prema bilo kojem prethodnom zahtjevu, naznačen time, da je transport sumporne kiseline preko spomenute membrane pospješen prolaskom prijamne tekućine na filtratnoj strani membrane, a ta prijamna tekućina je najbolje voda.
or a pharmaceutically acceptable salt thereof, or a derivative thereof wherein the amino group of the amidino-moiety is protected by hydroxyl or a (1-6C)alkoxycarbonyl group; 
ili njegova farmaceutski prihvatljiva sol, ili njegov derivat, gdje je amino skupina u amidino ostatku zaštićena hidroksilnom ili (1-6C)alkoksikarbonilnom skupinom;
wherein the spacer of the compound of formula I further comprises at least one covalent bond with a biotin residue. 
gdje razmaknica u spoju formule I dodatno sadrži najmanje jednu kovalentnu vezu s biotinskim ostatkom.
The compound of claim 1, wherein the pentasaccharide residue has the structure wherein R5 is OCH3 or OSO3-. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što pentasaharidni ostatak ima strukturu [image] gdje R5 je OCH3 ili OSO3–.
The compound of any of claims 1 to 10, wherein the spacer of the compound of formula I comprises one covalent bond with a residue of a biotin analogue of the formula -(CH2)4-NR- BT, wherein R is H or (1-4C)alkyl and BT is the residue 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što razmaknica u spoju formule I sadrži jednu kovalentnu vezu s ostatkom biotinskog analoga formule -(CH2)4-NR-BT, gdje R je H ili (1-4C)alkil, a BT je ostatak [image] .
The compound of claim 11, being or a pharmaceutically acceptable salt thereof, or a derivative thereof wherein the amino group of the amidino-moiety is protected by hydroxyl or a (1-6C)alkoxycarbonyl group. 
Spoj u skladu s patentnim zahtjevom 11, naznačen time što je [image] ili njegova farmaceutski prihvatljiva sol, ili njegov derivat, gdje je amino skupina u amidino ostatku zaštićena hidroksilnom ili (1-6C)alkoksikarbonilnom skupinom.
The compound of claim 12, being in the form of its sodium salt. 
Spoj u skladu s patentnim zahtjevom 12, naznačen time što je u obliku svoje soli s natrijem.
A process for the preparation of the compound of formula I of claim 1 comprising a step wherein the benzamidine moiety in the residue A is in the form of a precursor, being the 1,2,4-oxadiazolin-5-one group, and is subsequently converted into the benzamidine by deprotection. 
Postupak dobivanja spoja formule I u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u koraku u kojem je benzamidinski ostatak u ostatku A u obliku preteče, kao 1,2,4-oksadiazolin-5-onska skupina, i naknadno se prevodi u benzamidin skidanjem zaštite.
The compound according to claim 2 wherein the substituent of phenyl at R4 is R5,R6-aminocarbonyl, (1-4C)alkoxy and/or halogen. 
Spoj u skladu s patentnim zahtjevom 2, naznačen time što supstituent fenila na položaju R4 je R5,R6-aminokarbonil, (1-4C)alkoksi i/ili halogen.
Use of the compound of any one of claims 1-9 including 2-methyl-5-oxo-7-phenyl-4-(3,4,5-trimethoxyphenyl)-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile, or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of fertility disorders. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1-9, uključujući 2-metil-5-okso-7-fenil-4-(3,4,5-trimetoksifenil)-1,4,5,6,7,8-heksahidrokinolin-3-karbonitril, ili njegove farmaceutski prihvatljive soli ili solvata, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje poremećaja plodnosti.
a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 90 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 43; 
varijabilno područje teškog lanca koje sadrži aminokiselinski slijed prikazan u SEQ ID NO: 90 i varijabilno područje lakog lanca koje sadrži aminokiselinski slijed prikazan u SEQ ID NO: 43;
ii) a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 92 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 42; 
ii) varijabilno područje teškog lanca koje sadrži aminokiselinski slijed prikazan u SEQ ID NO: 92 i varijabilno područje lakog lanca koje sadrži aminokiselinski slijed prikazan u SEQ ID NO: 42;
The antibody or antigen-binding fragment thereof of claim 1 or claim 2, further comprising an IgG4 constant region having the amino acid sequence shown in SEQ ID NO: 40 and a kappa chain constant region having the amino acid sequence shown in SEQ ID NO: 41. 
Protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačeno time što dodatno sadrži konstantno područje IgG4 koje ima aminokiselinski slijed prikazan u SEQ ID NO: 40 i konstantno područje k lanca koje ima aminokiselinski slijed prikazan u SEQ ID NO: 41.
to 3 % (w/w) of a difunctional acrylate or methacrylate cross-linking monomer of formula [2]: wherein 
0,5 do 3 % (težinski) difunkcionalnog akrilatnog ili metakrilatog umrežavajućeg monomera formule [2]: [image] gdje
The polymeric device material of Claim 1 wherein the amount of monomer [1] is 70 to 90 % (w/w). 
Polimerni materijal za navedene uređaje u skladu s patentnim zahtjevom 1, naznačen time što količina monomera [1] je 70 do 90 % (težinski).
The polymeric device material of Claim 9 wherein the amount of hydrophilic side-chain macromer is 10 to 20 % (w/w). 
Polimerni materijal za navedene uređaje u skladu s patentnim zahtjevom 9, naznačen time što količina hidrofilnog pobočnog makromera je 10 do 20 % (težinski).
The polymeric device material of Claim 1 further comprising an ingredient selected from the group consisting of a polymerizable UV absorbers and a polymerizable colorants. 
Polimerni materijal za navedene uređaje u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži sastojak kojeg se bira iz skupine koju čine polimerizabilni UV apsorberi i polimerizabilne boje.
A process for preparing a polymeric ophthalmic or otorhinolaryngological device material according to claim 1 wherein the ingredients [1], [2] and [3] along with any further optional ingredients are combined and polymerized using a radical initiator to initiate polymerization by the action of either heat or radiation, 
Postupak priprave polimernog materijala za oftalmički ili otorinolaringološki uređaj u skladu s patentnim zahtjevom 1, naznačen time što sastojke [1], [2] i [3], kao i sve daljnje izborne sastojke se međusobno miješa, te polimerizira uz upotrebu radikalnog inicijatora za započinjanje polimerizacije, uz djelovanje bilo topline ili zračenja.
is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, aminoacyl, aryl, substituted aryl, halo, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, and —XR6 where X is oxygen, —S(O)n— or —NR7— where n is zero, one or two, R6 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic, and R7 is hydrogen, alkyl or aryl or, when X is —NR7—, then R7 and R6, together with the nitrogen atom to which they are bound, can be joined to form a heterocyclic or substituted heterocyclic group; 
je odabran iz skupine koja sadrži vodik, alkil, supstituirani alkil, alkoksi; supstituirani alkoksi, amino, supstituirani amino, aminoacil, aril, supstituirani aril, halo, heteroaril, supstituirani heteroaril, heterociklički, supstituirani heterociklički, i - XR6 gdje X je kisik, -S(O)n- ili -NR7- gdje n je nula, jedan ili dva, R6 je odabran iz skupine koja sadrži alkil, supstituirani alkil, aril, supstituirani aril, heteroaril, supstituirani heteroaril, heterocikal i supstituirani heterocikal, i R7 je vodik, alkil ili aril ili, kada X je -NR7-, tada R7 i R6, zajedno sa atomom dušika na koji su vezani, mogu se spajati da formiraju heterocikličku ili supstituiranu heterocikličku skupinu;
R″ is selected from the group consisting of hydrogen, alkyl and substituted alkyl; and 
R je odabran iz skupine koja sadrži vodik, deuterij i metil;
The method of claim 1, wherein R1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, halo, alkoxy, aryloxy, substituted aryloxy, substituted aryl, alkylthio, aminoacyl, aryl, substituted amino, heteroaryl, heteroaryloxy, —S(O)n-aryl, —S(O)n— substituted aryl, —S(O)n-heteroaryl, and —S(O)n-substituted heteroaryl, where n is zero, one or two. 
Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time da je R1 odabran iz skupine koja sadrži vodik, alkil, supstituirani alkil, halo, alkoksi, ariloksi, supstituirani ariloksi, supstituirani aril, alkiltio, aminoacil, aril, supstituirani amino, heteroaril, heteroariloksi, -S(O)n-aril, -S(O)n-supstituirani aril, -S(O)n-heteroaril, i -S(O)n-supstituirani heteroaril, gdje n je nula, jedan ili dva.
A dosage form comprising: 90 to 880 micrograms of fentanyl, calculated as fentanyl free base or an equivalent amount of a salt thereof, an effervescent couple in an amount of 5 to 85% by weight of the dosage form, a pH adjusting substance in an amount of 0.5 to 25% by weight of the dosage form, a starch glycolate in an amount of 0.25 to 20% by weight of the dosage form, and mannitol, said dosage form being suitable for delivery of said fentanyl across the oral mucosa of a patient by buccal, gingival or sublingual administration. 
Oblik doziranja naznačen time da sadrži 90 do 880 mikrograma fentanila, izračunato kao slobodna baza fentanila, ili ekvivalentnu količinu njegove soli, efervescentni par u količini od 5 do 85% težinskih od oblika doziranja, tvar za podešavanje pH u količini od 0,5 do 25% težinskih od oblika doziranja, škrob glikolat u količini od 0,25 do 20 težinskih od oblika doziranja, i manitol, a navedeni oblik doziranja je pogodan za dostavljanje navedenog fentanila kroz oralnu sluznicu pacijenta bukalnom, gingivalnom ili sublingvalnom primjenom.
A dosage form comprising 90 to 880 micrograms of fentanyl, calculated as fentanyl free base or an equivalent amount of a salt thereof, an effervescent couple, a pH adjusting substance, said adjusting substance selected and provided in an amount capable of providing a change in localized pH of at least 0.5 pH units, mannitol, and a starch glycolate, said dosage form being suitable for delivery of said fentanyl across the oral mucosa of a patient by buccal, gingival or sublingual administration and providing a ratio of Cmax to dose between 2.0 and 4.0 picograms/mL/microgram, wherein said dosage form is to be maintained in intimate contact with said oral mucosa for a time sufficient to deliver a therapeutically effective amount of said fentanyl across said oral mucosa, for use in the treatment of pain. 
Oblik doziranja naznačen time da sadrži 90 do 880 mikrograma fentanila, izračunato kao slobodna baza fentanila, ili ekvivalentnu količinu njegove soli, efervescentni par, tvar za podešavanje pH, navedena tvar za podešavanje je odabrana i dana u količini koja može pružiti promjenu u lokaliziranom pH od najmanje 0,5 pH jedinica, manitol i škrob glikolat, navedeni oblik doziranja je pogodan za dostavljanje navedenog fentanila kroz oralnu sluznicu pacijenta bukalnom, gingivalnom ili sublingvalnom primjenom i daje omjer Cmax prema dozi između 2,0 i 4,0 pikograma/mL/mikrogramu, pri čemu navedeni oblik doziranja treba biti u bliskom kontaktu sa navedenom oralnom sluznicom tijekom vremena dovoljnog da se dostavi terapeutski djelotvorna količina navedenog fentanila preko navedene oralne sluznice, za upotrebu kod liječenja boli.
The dosage form for use according to claim 9 wherein said pain is selected from the group consisting of breakthrough cancer pain, back pain, neuropathic pain, surgical pain, or post operative pain. 
Oblik doziranja za upotrebu prema zahtjevu 9, naznačen time da je navedena bol odabrana iz skupine koja se sastoji od cijelokupne boli zbog raka, boli u leđima, neuropatske boli, operativne boli ili post-operativne boli.
A method of making a tablet for buccal, gingival or sublingual administration of fentanyl comprising the steps of: providing fentanyl or a salt thereof in an amount of between 90 and 880 micrograms per dose measured as fentanyl base, or an equivalent amount of a salt thereof, providing an effervescent couple in an amount of 5 to 85% by weight of the dosage form, a pH adjusting substance in an amount of 0.5 to 25% by weight of the dosage form, a starch glycolate in an amount of 0.25 to 20% by weight of the dosage form and a filler in an amount of between 10% and 80% by weight of the dosage form, wherein said filler comprises mannitol, blending said fentanyl, effervescent couple, pH adjusting substance, said starch glycolate and said filler, and compressing the resulting blend into at least one tablet. 
Postupak za izradu tablete za bukalnu, gingivalnu ili sublingvalnu primjenu fentanila naznačen time da sadrži korake: davanja fentanila ili njegove soli u količini od između 90 i 880 mikrograma po dozi mjereno kao baza fentanila, ili ekvivalentne količine njegove soli, pružanja efervescentnog para u količini od 5 do 85% težinskih od oblika doziranja, tvari za podešavanje pH u količini od 0,5 do 25% težinskih od oblika doziranja, škrob glikolata u količini od 0,25 do 20% težinskih od oblika doziranja i punila u količini od između 10% i 80% težinskih od oblika doziranja, pri čemu navedeno punilo obuhvaća manitol, te miješanja navedenog manitola, efervescentnog para, tvari za podešavanje pH, navedenog škrob glikolata i navedenog punila, te kompresije dobivene smjese u barem jednu tabletu.
The method of claim 13 further comprising the step of adding a lubricant to said blend prior to compressing same into at least one tablet. 
Postupak prema patentnom zahtjevu 13 naznačen time da nadalje sadrži korak dodavanja lubrikanta navedenoj smjesi prije kompresije smjese u barem jednu tabletu.
The dosage form of claim 1 or 9, wherein the dosage form comprises no more than about 10% by weight of lactose monohydrate or microcrystalline cellulose and no more than about 4% crosslinked PVP. 
Oblik doziranja prema patentnom zahtjevu 1 ili 9, naznačen time da oblik doziranja sadrži ne više od približno 10% težinskih laktoza monohidrata ili mikrokristalne celuloze i ne više od približno 4% unakrsno povezanog PVP.
A compound, which is 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione or 3-(4-amino-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, for use in reduction of acquired antibody resistance in a cancer patient, wherein the compound is formulated for administration prior to the administration of an antibody. 
Spoj 4-(amino)-2-(2,6-diokso(3-piperidil))-izoindolin-1,3-dion ili 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)-piperidin-2,6-dion, naznačen time što se koristi za primjenu za izazivanje pojačanog imunog odgovora na cjepivo kod subjekta, pri čemu je spoj oblikovan za primjenu subjektu prije davanja cjepiva tom subjektu.
The compound of claim 1, wherein Y is a bond, SO2 or -O-(CO)-. 
Spoj prema zahtjevu 1, naznačen time, da Y je veza, SO2 ili -O-(CO)-.
The compound of claim 7, wherein R2 and J are independendy an optionally substituted phenyl. 
Spoj prema zahtjevu 7, naznačen time, da R2 i J su neovisno opcijski supstituirani fenil.
The compound of claim 7, wherein R3 is C1-6 alkyl or an optionally substituted benzyl. 
Spoj prema zahtjevu 7, naznačen time, da R3 je C1-6alkil ili opcijski supstituirani benzil.
The compound of claim 7, wherein R4 is an optionally substituted piperidinyl. 
Spoj prema zahtjevu 7, naznačen time, da R4 je opcijski supstituirani piperidinil.
The compound of claim 1, wherein said compound is selected from thte group consisting of: and or pharmaceutically acceptable salts thereof. 
Spoj prema zahtjevu 1, naznačen time, da spomenuti spoj je odabran iz skupine koja se sastoji od: [image] ili njegove farmaceutski prihvatljive soli.
The compound of claim 1, wherein said compound is selected from the group consisting of: or pharmaceutically acceptable salts thereof. 
Spoj prema zahtjevu 1, naznačen time, da spomenuti spoj je odabran iz skupine koja se sastoji od: [image] ili njegove farmaceutski prihvatljive soli.
A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any of claims 1-19. 
Farmaceutski sastav, naznačen time, da sadrži terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1-19.
Use of a compound of any one of claim 1-19 for the manufacture of a medicament for treating a condition mediated by a channel activating protease in a cell or tissue system or in a mammal, and optionally in combination with a second therapeutic agent; wherein said channel activating protease is prostasin, PRSS22, TMPRSS11 (e.g ., TMPRSS 11B, TMPRSS11E), TMPRSS2. 
Uporaba spoja prema bilo kojem od zahtjeva 1 do 19, naznačena time, da služi za proizvodnju lijeka za liječenje stanja prouzrokovanog proteazom kanalizirane aktivacije u stanici ili sustavu tkiva ili kod sisavaca, i opcijski u kombinaciji s drugim terapeutskim sredstvom, pri čemu spomenuta proteaza kanalizirane aktivacije je protazin, PRSS22, TMPRSS11 (npr. TMPRSS 11B, TMPRSS11E), TMPRSS2.
The use of claim 22 wherein said condition is associated with the movement of fluid across ion transporting epithelia or the accumulation of mucus and sputum in respiratory tissues, or a combination thereof. 
Uporaba prema zahtjevu 22, naznačena time, da spomenuto stanje je povezano s premještanjem tekućine preko epitela za transport iona ili s nakupljanjem sluzi i pljuvačke u respiratornom tkivu, ili s njihovom kombinacijom.
The use of claim 22, wherein said second therapeutic agent is an anti-inflammatory, bronchodilatory, andhistamine, anti-cussive, antibiotic or DNase, and is administered prior to, simultaneously with, or after the compound according to any of claims 1. 
Uporaba prema zahtjevu 22, naznačena time, da spomenuto drugo terapeutsko sredstvo je protuupalno, bronhodilatorno, histaminsko, antitusivno, antibiotičko ili DNase, i primjenjuje se prije, istovremeno sa, ili nakon davanja spoja prema bilo kojem od zahtjeva 1 do 19.
The end closure as claimed in claim 1 characterised in that its inside surface (2) of the body (1) of the end closure has a domed shape. 
Završni zatvarač prema zahtjevu 1, naznačen time što unutrašnja površina (2) tijela (1) završnog zatvarača ima kupolasti oblik.
The end closure as claimed in claim 1 or claim 2 characterised in that a plane section of the valve (5) has a shape close to a circular sector. 
Završni zatvarač prema zahtjevu 1 ili zahtjevu 2, naznačen time što ventil (5) u vodoravnom presjeku ima oblik blizak kružnom isječku.
The end closure as claimed in claim 3 characterised in that the surface of the valve (5) on the opposite side of the latches (7) consists of two planes (17 and 18) that have a common edge (15) running along the chord of the edge arch of the valve. 
Završni zatvarač prema zahtjevu 3, naznačen time što se površina ventila (5) na strani koja je suprotna u odnosu na zupce (7) sastoji od dvije ravnine (17 i 18) koje dijele zajednički rub (15) koji se proteže duž tetive rubnog luka ventila.
The end closure as claimed in claim 1 characterised in that the latches (7) have flanges (8). 
Završni zatvarač prema zahtjevu 1, naznačen time što zupci (7) imaju izbojak (8).
The end closure as claimed in claim 1 characterised in that it has a groove (16) on its inside surface (2), in a location where the foil is attached. 
Završni zatvarač prema zahtjevu 1, naznačen time što isti ima utor (16) na unutrašnjoj strani (2), na mjestu gdje je pričvršćena folija.
The end closure as claimed in claim 1 characterised in that the foil (11) is sealed to the inside surface (2) of the body (1) of the end closure. 
Završni zatvarač prema zahtjevu 1, naznačen time što je folija (11) čvrsto pričvršćena za unutrašnju površinu (2) tijela (1) završnog zatvarača.
The end closure as claimed in claim 1 characterised in that the mounting hole (4) is bored in the centre of the body (1) of the end closure. 
Završni zatvarač prema zahtjevu 1, naznačen time što je pričvrsna rupa (4) izbušena u središtu tijela (1) završnog zatvarača.
The end closure as claimed in claim 1 characterised in that the surface of the arm of the knob (13), which is facing the outside surface of the end closure, has a shape close to a circular sector and serves as a hygienic cover (19). 
Završni zatvarač prema zahtjevu 1, naznačen time što površina poluge na izbočini (13), a koja je okrenuta prema vanjskoj površini završnog zatvarača, ima oblik blizak kružnom isječku te služi kao higijenski poklopac (19).
The end closure as claimed in claim 1 through to 9 characterised in that the hygienic cover (19) is firmly fitted in a hole (20) in the arm (13) of the knob (6). 
Završni zatvarač prema zahtjevima 1 do 9, naznačen time što higijenski poklopac (19) čvrsto naliježe u rupu (20) u poluzi (13) na izbočini (6).
The end closure as claimed in claim 1 through to 9 characterised in that it has a snap-on hygienic cover (19). 
Završni zatvarač prema zahtjevima 1 do 9, naznačen time što ima higijenski poklopac (19) na prikapčanje.
A compound of the general formula I: wherein the sulphur atom is attached to the indole via any ring carbon of the indole and wherein 
Spoj opće formule I: [image] naznačen time što je atom sumpora pričvršćen za indol preko bilo kojeg atoma ugljika u indolovom prstenu i pri čemu
with the provisos that: 
uz uvjete da:
when the sulphur atom is attached via atom nr. 
kada je atom sumpora pričvršćen preko atoma br.